Actively Recruiting
Phase 1a1b Study of NPX887 to Find Safe Dose and Test Effectiveness in Treating Solid Tumors Expressing B7-H7HHLA2
Led by NextPoint Therapeutics, Inc. · Updated on 2025-06-27
144
Participants Needed
8
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating NPX887, a human monoclonal antibody targeting B7-H7 HHLA2, in people with solid tumors that express this protein. This first-in-human study aims to determine if NPX887 is safe and tolerable, identify the appropriate dose, and assess preliminary anti-tumor effects. The trial focuses on tumors that have not responded to or are intolerant of standard treatments, with careful monitoring for side effects and early signs of effectiveness. The study consists of Phase 1a Dose Escalation and Phase 1b including Dose Expansion and Randomized Dose Comparison. Participants will receive NPX887 through intravenous infusion every three weeks for up to two years or until disease progression, unacceptable toxicity, withdrawal, or investigator decision. Blood and tumor tissue samples will be collected at screening and during treatment for biomarker and pharmacodynamic analysis. Phase 1a identifies optimal dosing, while Phase 1b evaluates the treatments activity in specific tumor types and compares higher and lower doses. Participants will undergo regular assessments including safety monitoring for adverse events, dose-limiting toxicities, and treatment interruptions. Researchers will measure outcomes such as objective response rate, duration of response, disease control rate, progression-free survival, and overall survival up to two years. Blood samples will track the drugs concentration and immune responses. The study involves monitoring for up to 24 months with evaluations of tumor tissue and blood to understand how NPX887 acts in the body and affects the tumors.
CONDITIONS
Brief Title
A Study of NPX887 for Participants With Solid Tumors Known to Express B7-H7/HHLA2
Research Team
T
Trials nextpointtx
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here